Infectious Complications in Biologic and Targeted Therapies

Häftad, Engelska, 2023

1 599 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies.

Produktinformation

Utgivningsdatum2023-11-19
Mått155 x 235 x 25 mm
Vikt815 g
FormatHäftad
SpråkEngelska
Antal sidor473
FörlagSpringer International Publishing AG
ISBN9783031113659

Tillhör följande kategorier

Klinisk medicin och internmedicin inom Medicin

Carlos Cervera, MD, PhDDivision of Infectious Diseases, Department of Medicine. University of Alberta.1-124F Clinical Sciences Building. 11350 83 Ave. Edmonton T6G 2G3Alberta, CanadaPrimary email address: cerveraa@ualberta.caJose Maria Aguado, MD, PhDUnit of Infectious Diseases, Research Institute Hospital "12 de Octubre" (i + 12),University Hospital “12 de Octubre”, Complutense University of MadridMadrid, SpainPrimary email address: jaguadog1@gmail.com

Overview on the risk of infection associated with biologic and targeted therapies.- Timeline of infections associated with biologic and targeted therapies.- Infectious disease evaluation of candidates to new therapies.- Vaccines and biologic and targeted therapies.- Travel and risk of infections.- Anti-necrosis tumoral factor-alpha agents.- CD19-targeted agents.- CD20-targeted agents.- CD22-targeted agents.- CD30-targeted agents.- CD33 and CD38-targeted agents.- CD40 and CD319-targeted agents.- CD52-targeted agents.- CCR4-targeted agents.- Cell-surface receptors I: VEFG targeted agents.- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents.- Interleukin-1 targeted agents.- Interleukin-5 and interleukin-6 targeted agents.- Interleukin-12/23 p40 targeted agents.- Sphingosine-1 phosphate receptor modulators.- Immune checkpoint inhibitors.- α4-integrin-targeted agents.- Tyrosin-kinase inhibitors.- Bcl-2, JAK and mTOR inhibitors.- Infections associated with the use ofCarT cells.- Pulmonary infiltrates.- Tuberculosis.- Cytomegalovirus and other herpesviruses.- Invasive fungal infections.- Progressive multifocal leukoencephalopathy.- Hepatitis virus.